KR102486025B1 - Composition for feminine cleanser comprising live lactic acid bacteria and helpful for improving vaginitis - Google Patents
Composition for feminine cleanser comprising live lactic acid bacteria and helpful for improving vaginitis Download PDFInfo
- Publication number
- KR102486025B1 KR102486025B1 KR1020220117612A KR20220117612A KR102486025B1 KR 102486025 B1 KR102486025 B1 KR 102486025B1 KR 1020220117612 A KR1020220117612 A KR 1020220117612A KR 20220117612 A KR20220117612 A KR 20220117612A KR 102486025 B1 KR102486025 B1 KR 102486025B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactic acid
- acid bacteria
- composition
- present
- extract
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 122
- 241000894006 Bacteria Species 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 239000004310 lactic acid Substances 0.000 title claims abstract description 61
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 61
- 206010046914 Vaginal infection Diseases 0.000 title description 23
- 201000008100 Vaginitis Diseases 0.000 title description 23
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 41
- 241000965142 Leuconostoc kimchii Species 0.000 claims abstract description 38
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 37
- 239000000284 extract Substances 0.000 claims abstract description 37
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 37
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 235000000039 Opuntia compressa Nutrition 0.000 claims abstract description 16
- 241000454613 Opuntia humifusa Species 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 9
- 241000222122 Candida albicans Species 0.000 abstract description 24
- 229940095731 candida albicans Drugs 0.000 abstract description 23
- 241000207201 Gardnerella vaginalis Species 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 12
- 239000002537 cosmetic Substances 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- 239000002609 medium Substances 0.000 description 33
- 239000007788 liquid Substances 0.000 description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 235000021109 kimchi Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000001215 vagina Anatomy 0.000 description 11
- 241000192132 Leuconostoc Species 0.000 description 10
- -1 patch Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000003905 vulva Anatomy 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 6
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000009422 growth inhibiting effect Effects 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007890 Leonurus cardiaca Species 0.000 description 2
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000037009 Vaginitis bacterial Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000207543 Euphorbia heterophylla Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000265736 Nelumbo pentapetala Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000004727 Opuntia ficus indica Nutrition 0.000 description 1
- 240000009297 Opuntia ficus-indica Species 0.000 description 1
- 241001114012 Opuntioideae Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004978 Rosa x damascena Species 0.000 description 1
- 235000011402 Rosa x damascena Nutrition 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002828 disc diffusion antibiotic sensitivity testing Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Abstract
Description
본 발명은 여성청결제용 조성물에 관한 것으로서, 더 상세하게는 소정의 혼합 유산균 및 소정의 식물 추출물을 포함하여 여성 외음부의 가려움 또는 질염 등을 유발하는 칸디다 알비칸스(Candida albicans) 균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균의 생장을 효과적으로 억제할 수 있는 여성청결제용 조성물에 관한 것이다.The present invention relates to a composition for a female cleanser, and more particularly, to a composition containing a certain mixed lactic acid bacteria and a certain plant extract, which causes itching or vaginitis in the female vulva, Candida albicans bacteria and Gardnerella pants It relates to a composition for a feminine cleanser capable of effectively inhibiting the growth of Gardnerella Vaginalis bacteria.
여성의 질은 외음부와 자궁의 연결 통로로 여성의 몸에서 가장 습기가 많고 따뜻한 곳이다. 따라서, 질염의 주원인인 세균이나 곰팡이가 서식하기 적합한 환경이므로 그로 인한 질환이 발생할 가능성이 크다. 정상적인 조건에서는 질 내부에 많은 유산균이 서식하면서 질 내부를 약산성으로 만들어 병원균이나 곰팡이가 증식하는 것을 억제하지만, 항생제 장기복용이나 피임약 장기복용, 탐폰이나 루프사용 또는 임신이나 출산, 수유, 폐경 등으로 여성 호르몬의 균형 변화 등의 이유로 질 내부의 균형이 깨어질 때 질 내에서 정상적인 조건에서는 성장이 통상적으로 억제되는 기회감염성 병원체의 증식이 일어나 질염이 발병할 수 있다. 질염은 세균성 질염(bacterial vaginosis), 칸디다성 질염(Candida vaginitis), 트리코모나스 질염(Trichomonas vaginitis), 위축성 질염(Atrophic vaginitis)등이 보고되어 있다.The vagina is the most moist and warm place in a woman's body as it connects the vulva and uterus. Therefore, since it is an environment suitable for the habitat of bacteria or fungi, which are the main causes of vaginitis, there is a high possibility of diseases caused therefrom. Under normal conditions, many lactic acid bacteria live inside the vagina, making the inside of the vagina slightly acidic to suppress the growth of pathogens or fungi. When the balance in the vagina is disturbed due to a change in hormone balance, opportunistic pathogens, which are normally suppressed in growth under normal conditions, proliferate in the vagina, resulting in vaginitis. Bacterial vaginosis, Candida vaginitis, Trichomonas vaginitis, and atrophic vaginitis have been reported for vaginitis.
세균성 질염과 함께 흔한 질환인 칸디다성 질염(Candida vaginitis)은 진균인 칸디다 알비칸스(Candida albicans) 균이 습한 음부에 서식하면서 염증을 일으키는 질환으로서, 약 75%의 여성이 살아가는 동안 한 번 이상 질과 외음부의 칸디다성 질염을 겪으며 45%의 여성이 1년에 2회 이상의 재발을 겪는 흔한 질환이다. 건강한 사람의 구강, 장, 질 등에 정상적으로 보유하고 있는 칸디다(주로 Candida albicans)가 임신이나 경구용 피임약 장기 복용 등으로 여성 호르몬의 상태가 비정상적일 때, 감기나 당뇨병, 에이즈의 이유로 면역성이 극도로 쇠약할 때 감염을 유발하게 된다. 비만, 항생제의 알레르기나 관절염 등의 치료제로 쓰이는 부신 피질 호르몬의 복용 등에 의해서도 발병할 수 있다. 항생제의 투여로 인한 발병의 경우 항생제가 질 내의 유익한 유산균을 죽임으로써 발생하는데 이런 경우 재발의 가능성도 크다. 너무 꼭 끼는 거들이나 바지 등을 입어 통풍이 안 되거나 목욕 후 외음부의 물기를 잘 닦지 않아 젖은 팬티를 입은 경우, 생리 중 패드를 자주 갈지 않는 경우에도 잘 발생한다. 질에 칸디다 알비칸스가 서식하고 있는 여성의 50%만이 증상이 있는데 주증상은 냉이 많아지고 피부에 염증 반응이 생겨서 가려운 것이며, 병의 종류와 정도 또는 2차 세균 감염 등에 따라서 피부가 벗겨지거나 고름이 나오는 등 차이가 있다. 특징적 증상으로는 짙고 하얀 분비물이 나오며, 외음부는 매우 신경이 예민하여 아프거나 때로 부종과 염증이 생기기도 한다. 작열감, 성교통, 부종, 외음부 통증 등이 있고 임상 소견으로는 외음부 및 질의 홍반, 울혈, 표피박리, 소포, 농포, 등을 볼 수 있다.Candida vaginitis, a common disease along with bacterial vaginosis, is a disease in which the fungus Candida albicans inhabits the moist genital area and causes inflammation. Vaginal candidal vaginitis is a common disease in which 45% of women experience two or more recurrences per year. Candida (mainly Candida albicans), normally present in the mouth, intestines, and vagina of healthy people, is abnormal when female hormones are abnormal due to pregnancy or long-term use of oral contraceptives, and immunity is extremely weakened due to colds, diabetes, or AIDS. Doing so will cause infection. It can also be caused by taking corticosteroids used as a treatment for obesity, allergy to antibiotics, or arthritis. In the case of outbreaks caused by administration of antibiotics, antibiotics kill beneficial lactic acid bacteria in the vagina, and in this case, the possibility of recurrence is high. It can also occur if you wear a tight girdle or pants that do not allow ventilation, or if you do not wipe the vulva well after bathing and wear wet panties, or if you do not change your pads often during menstruation. Only 50% of women living with Candida albicans in the vagina have symptoms. There is a difference between coming out. Characteristic symptoms include thick and white discharge, and the vulva is very sensitive, causing pain or sometimes swelling and inflammation. There are burning sensation, dyspareunia, edema, vulvar pain, etc. Clinical findings include erythema of the vulva and vagina, congestion, epidermal detachment, vesicles, pustules, etc.
상기 칸디다성 질염을 예방하기 위해 여성 청결제, 외음부 세정제 또는 질 세정제와 같은 제품을 많이 이용하지만 실제로 효능이 미미하거나, 민감한 부위에 맞지 않는 화학성분을 함유하고 있는 경우가 있다. 또한, 칸디다성 질염을 치료하기 위해 사용하는 fluconazole과 같은 Azole계 항진균제의 경우 이에 대해 내성을 갖는 균주가 보고되고 있다. 상기와 같은 항진균제가 적절한 항생제라 할지라도, 충분치 못 한 양을 투여했을 경우에는 병균은 죽지 않고 내성으로 인하여 오히려 차후 치료에 더 큰 어려움을 낳는다. 또한 세정제로 사용되는 물리화학적 질 세정제는 장기간 사용시 세정 효과가 저하되고 잡균은 제거되는 대신 진균이 증가하며, 악취 및 불쾌한 냄새 제거 효과가 저해되는 등 한계가 존재하였다.In order to prevent candida vaginitis, products such as female cleaners, vulvar cleaners, or vaginal cleaners are often used, but they may actually have little effect or contain chemical components that are not suitable for sensitive areas. In addition, in the case of Azole antifungal agents such as fluconazole used to treat candidal vaginitis, strains resistant to them have been reported. Even if the above antifungal agent is an appropriate antibiotic, if an insufficient amount is administered, the pathogen does not die and rather causes greater difficulties in subsequent treatment due to resistance. In addition, physicochemical vaginal detergents used as detergents have limitations such as deterioration of cleaning effect when used for a long time, increase of fungi instead of removal of germs, and inhibition of odor and unpleasant odor removal effects.
이러한 결점 등을 해결하기 위해 최근 생약 기반의 질염 치료제 또는 여성청결제가 개발되고 있다. 예를 들어, 대한민국 등록특허공보 제10-2036339호에는 유백피, 익모초 및 토복령 혼합 추출물을 포함하는 여성청결제용 조성물이 개시되어 있다. 또한, 대한민국 등록특허공보 제10-1983990호에는 초정약수 2~40 중량%; 익모초 추출물, 쑥 추출물 및 녹차 추출물의 혼합물 0.01~3 중량%; 및 정제수 45~95 중량%를 함유하는 여성 청결제 조성물이 개시되어 있다. 또한, 대한민국 등록특허공보 제10-1870780호에는 다마스크 장미꽃오일, 금잔화꽃수, 라벤더꽃수, 홍차 추출물 및 프로폴리스 추출물을 유효성분으로 포함하는 여성용 청결제 조성물이 개시되어 있다. 또한, 대한민국 등록특허공보 제10-1345709호에는 중량비 기준 고삼 1.0~4.0 : 단삼 20~40 : 사상자 1.0~4.0 : 지부자 1.0~4.0 : 황금 40~60 : 황련 5.0~15 : 황백 1.0~4.0로 구성하여 혼합된 천연 생약재를 추출용매를 이용하여 추출한 천연 생약재 추출물을 포함하고, 진균류인 칸디다알비칸스(Candida albicans)와 일반세균인 가드네렐라 바지날리스(Gardnerella Vaginalis)에 항균활성 효과가 있는 항균제 조성물이 개시되어 있다. In order to solve these drawbacks, herbal medicine-based vaginitis treatments or feminine cleansers have recently been developed. For example, Korean Patent Registration No. 10-2036339 discloses a composition for a feminine cleanser containing a mixed extract of milkweed, motherwort, and tobokryeong. In addition, Korean Patent Registration No. 10-1983990 discloses 2 to 40% by weight of pure mineral water; 0.01 to 3% by weight of a mixture of motherwort extract, mugwort extract and green tea extract; And a feminine cleanser composition containing 45 to 95% by weight of purified water is disclosed. In addition, Korean Patent Registration No. 10-1870780 discloses a feminine cleanser composition containing damask rose flower oil, marigold flower water, lavender flower water, black tea extract and propolis extract as active ingredients. In addition, Korean Patent Registration No. 10-1345709, based on weight ratio, high ginseng 1.0 ~ 4.0: Dansam 20 ~ 40: casualty 1.0 ~ 4.0: branch 1.0 ~ 4.0: gold 40 ~ 60: yellow lotus 5.0 ~ 15: yellow white 1.0 ~ 4.0 An antibacterial composition containing natural herbal medicine extracts obtained by extracting natural herbal medicines mixed using an extraction solvent and having antibacterial activity against Candida albicans , which is a fungus, and Gardnerella vaginalis , which is a general bacterium. This is disclosed.
또한, 생약 기반 외에 유산균 기반의 질염 치료제 또는 여성청결제가 개발되고 있다. 예를 들어 대한민국 등록특허공보 제10-1784847호에는 (1) 용융소금, 정제소금 또는 천일염으로부터 선택된 소금; (2) 자일로스(xylose), 아라비노스(arabinose), 글루코스(glucose), 만노스(mannose), 과당(fructose), 갈락토스(galactose), 락툴로오스(lactulose), 락티톨(lactitol), 설탕(sucrose), 유산(lactose), 말토스(maltose), 트레할로스(trehalose), 프럭토-올리고당(fructo-oligosaccharide), 라피노스(raffinose), 스타키오스(stachyose), 말토덱스트린(maltodextrin), 아밀로스(amylose), 아밀로펙틴(amylopectin), 전분(starch), 셀룰로오스(cellulose), 및 펙틴(pectin) 으로 구성된 군으로부터 선택된 당; 및 (3) 락토바실러스 에시도필루스(Lactobacillus acidophilus; KCTC No3164), 비피도박테리움 롱굼 아종 롱굼 (Bifidobacterium longum subsp longum; KCTC No 3128), 스트렙코코커스 종 균주 (Streptococcus sp; KCTCNo5644) 및 바실러스 세레우스 (Bacillus cereus; KCTC No 13123) 균주로 구성된 군으로부터 선택된 하나 이상의 유산균으로 구성된 배합물을 유효성분으로 함유하는 질염의 예방 및 개선용 세정제 조성물이 개시되어 있다. 또한, 대한민국 등록특허공보 제10-1833832호에는 (1) 용융소금, 정제소금 또는 천일염으로부터 선택된 소금; (2) 포도당, 과당, 락툴로오스, 락티톨 및 프럭토올리고당으로 구성된 군으로부터 선택된 당; 및 (3) 락토바실러스 브레비스(Lactobacillus brevis, KCTC No 13094), 락토바실러스 카세이 (Lactobacillus casei, KCTC No13086), 락토바실러스 델브루케키 아종 불가리쿠스(Lactobacillus delbrueckii subsp bulgaricus, KCTC No 3635), 락토바실러스 카세이 아종 카세이(Lactobacillus casei subsp casei, KCTC No 3260), 락토바실러스 델브루케키 아종 델브루케키(Lactobacillus delbrueckii subsp delbrueckii, KCTC No 13721), 비피도박테리움 아돌레센티스(Bifidobacterium adolescentis, KCTC No3267), 비피도박테리움 비피둠 (Bifidobacterium bifidum KCTC No3357), 비피도박테리움 브레브 (Bifidobacterium breve, KCTC No3441), 및 비피도박테리움 카테눌라툼(Bifidobacterium catenulatum, KCTC No3221) 균주로 구성된 군으로부터 선택된 하나 이상의 유산균으로 구성된 배합물을 유효성분으로 함유하는 질염의 예방 및 개선용 세정제 조성물이 개시되어 있다.In addition to herbal medicines, lactic acid bacteria-based vaginitis treatments or feminine cleansers are being developed. For example, Korean Patent Registration No. 10-1784847 discloses (1) salt selected from molten salt, refined salt or sun salt; (2) xylose, arabinose, glucose, mannose, fructose, galactose, lactulose, lactitol, sugar ( sucrose, lactose, maltose, trehalose, fructo-oligosaccharide, raffinose, stachyose, maltodextrin, amylose A sugar selected from the group consisting of amylopectin, starch, cellulose, and pectin; and (3) Lactobacillus acidophilus (KCTC No3164), Bifidobacterium longum subsp longum (KCTC No 3128), Streptococcus sp; KCTCNo5644 and Bacillus cerebrum. Disclosed is a detergent composition for preventing and improving vaginitis containing a combination consisting of one or more lactic acid bacteria selected from the group consisting of Bacillus cereus (KCTC No 13123) strains as an active ingredient. In addition, Korean Patent Registration No. 10-1833832 discloses (1) salt selected from molten salt, refined salt or bay salt; (2) a sugar selected from the group consisting of glucose, fructose, lactulose, lactitol and fructooligosaccharides; And (3) Lactobacillus brevis (KCTC No 13094), Lactobacillus casei (KCTC No13086), Lactobacillus delbrueckii subsp bulgaricus (KCTC No 3635), Lactobacillus casei subspecies Casei (Lactobacillus casei subsp casei, KCTC No 3260), Lactobacillus delbrueckii subsp delbrueckii (KCTC No 13721), Bifidobacterium adolescentis (KCTC No3267), Bifidobacterium Composed of one or more lactic acid bacteria selected from the group consisting of Bifidobacterium bifidum KCTC No3357, Bifidobacterium breve (KCTC No3441), and Bifidobacterium catenulatum (KCTC No3221) strains Disclosed is a detergent composition for preventing and improving vaginitis containing the combination as an active ingredient.
그러나, 상기 선행기술들에 제시된 여성 청결제는 그 효과가 미비하여 유효성분의 사용량이 매우 높다는 문제가 있다.However, the feminine cleanser presented in the prior art has a problem in that the effect is insufficient and the amount of active ingredient is very high.
본 발명은 종래의 기술적 배경하에서 도출된 것으로서, 본 발명의 목적은 질염의 가장 큰 원인균인 칸디다 알비칸스(Candida albicans) 균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균에 대해 우수한 항진균 활성을 보이면서 자극성과 부작용이 없어 보다 경제적이고 안전한 신규 여성청결제용 조성물을 제공하는데에 있다.The present invention was derived under the conventional technical background, and an object of the present invention is to exhibit excellent antifungal activity against Candida albicans bacteria and Gardnerella vaginalis bacteria, which are the biggest causes of vaginitis. It is to provide a more economical and safer novel composition for feminine cleansers without irritation and side effects.
본 발명의 발명자들은 다양한 유산균들과 식물 추출물들의 병용 처리에 의한 칸디다 알비칸스(Candida albicans) 균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균의 생장 억제 효과를 조사하였고, 그 중 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균, 류코노스톡 김치아이(Leuconostoc kimchii) 유산균 및 천년초(Opuntia humifusa) 추출물을 병용 처리시 칸디다 알비칸스(Candida albicans) 균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균의 생장 억제에 대해 우수한 시너지 효과를 나타낸다는 점을 확인하고, 본 발명을 완성하였다.The inventors of the present invention investigated the growth inhibitory effect of Candida albicans bacteria and Gardnerella vaginalis bacteria by the combined treatment of various lactic acid bacteria and plant extracts, among which Lactobacillus planta Room ( Lactobacillus plantarum ) Lactobacillus, Leuconostoc kimchii ( Leuconostoc kimchii ) Lactobacillus, and Cheonnyeoncho (Opuntia humifusa) extract are treated in combination with Candida albicans ( Candida albicans ) and Gardnerella vaginalis (Gardnerella Vaginalis) growth It was confirmed that it exhibits an excellent synergistic effect on inhibition, and the present invention was completed.
상기 목적을 해결하기 위하여, 본 발명은 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 또는 이를 포함하는 배양물에서 선택되는 제1유산균, 류코노스톡 김치아이(Leuconostoc kimchii) 유산균 또는 이를 포함하는 배양물에서 선택되는 제2유산균, 및 천년초(Opuntia humifusa) 추출물을 유효성분으로 포함하는 여성청결제용 조성물을 제공한다.In order to solve the above object, the present invention is Lactobacillus plantarum Lactobacillus plantarum Lactobacillus plantarum Lactobacillus or a first lactic acid bacteria selected from a culture containing the same, Leuconostoc kimchi child ( Leuconostoc kimchii ) Lactobacillus or a culture containing the same It provides a composition for a feminine cleanser comprising a selected second lactic acid bacterium and an extract of cheonnyeoncho ( Opuntia humifusa ) as an active ingredient.
본 발명에 따른 여성청결제용 조성물의 유효성분으로 사용되는 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균, 류코노스톡 김치아이(Leuconostoc kimchii) 유산균 및 천년초(Opuntia humifusa) 추출물은 병용 처리시 칸디다 알비칸스(Candida albicans) 균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균의 생장 억제에 대해 우수한 시너지 효과를 나타내고 인체에 유익한 유산균 및 식물에서 유래하기 때문에 자극성과 부작용이 없다. 따라서, 본 발명에 따른 여성청결제용 조성물은 의약품, 화장품, 퍼스널 케어 제품 등으로 활용될 수 있다. Lactobacillus plantarum lactic acid bacteria, Leuconostoc kimchii lactic acid bacteria and Opuntia humifusa extract used as active ingredients in the composition for feminine cleansers according to the present invention are used in combination treatment to prevent Candida albicans ( Candida albicans ) and Gardnerella vaginalis (Gardnerella Vaginalis) shows excellent synergistic effects against the growth inhibition and has no irritation or side effects because it is derived from lactic acid bacteria and plants beneficial to the human body. Therefore, the composition for a feminine cleanser according to the present invention can be used as medicines, cosmetics, personal care products, and the like.
본 발명에서 사용되는 용어인 "여성청결제"는 여성의 외음부에 사용되는 전용 클렌저로서, 여성 외음부 세정제 또는 질 세정제를 포함하는 개념이다.The term "female cleanser" used in the present invention is a cleanser exclusively used for the vulva of women, and is a concept that includes female vulva cleansers or vaginal cleansers.
본 발명에서 사용되는 용어인 "배양물'은 미생물 배양액을 동결건조 등의 방법으로 고형화시킨 것으로서 균체 및 미생물 배양에 의해 생성되는 대사산물을 포함하는 개념이다.The term "culture" used in the present invention is a solidification of a microbial culture medium by a method such as freeze-drying, and is a concept including cells and metabolites produced by microbial culture.
본 발명에서 사용되는 용어인 "약학적으로 허용가능한"이란 생물체를 상당히 자극하지 않고 투여 활성 물질의 생물학적 활성 및 특성을 저해하지 않는 것을 의미한다.As used herein, the term "pharmaceutically acceptable" means that it does not significantly stimulate living organisms and does not inhibit the biological activity and properties of the active substance administered.
본 발명에서 사용되는 용어인 "예방"는 본 발명의 조성물의 투여로 특정 질환의 증상을 억제하거나 진행을 지연시키는 모든 행위를 의미한다.As used herein, the term "prevention" refers to any action that suppresses symptoms or delays the progression of a specific disease by administering the composition of the present invention.
본 발명에서 사용되는 용어인 "개선"은 치료되는 상태와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미한다.As used herein, the term "improvement" refers to any action that at least reduces the severity of a parameter related to the condition being treated, for example, a symptom.
본 발명에서 사용되는 용어인 "치료"는 본 발명의 조성물의 투여로 특정 질환의 증상을 호전 또는 이롭게 변경시키는 모든 행위를 의미한다.The term "treatment" used in the present invention refers to all activities that improve or beneficially change the symptoms of a specific disease by administration of the composition of the present invention.
본 발명에서 사용되는 용어인 "투여"는 임의의 적절한 방법으로 개체에 소정의 본 발명의 조성물을 제공하는 것을 의미한다. 이때, 개체는 본 발명의 조성물을 투여하여 특정 질환의 증상이 호전될 수 있는 질환을 가진 인간, 원숭이, 개, 염소, 돼지 또는 쥐 등 모든 동물을 의미한다.As used herein, the term "administering" means providing a given composition of the present invention to a subject by any suitable method. In this case, the subject refers to all animals such as humans, monkeys, dogs, goats, pigs, or rats having a disease in which symptoms of a specific disease can be improved by administering the composition of the present invention.
본 발명에서 사용되는 용어인 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜 또는 위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 이는 개체의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출비율, 치료기간, 동시에 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit or risk ratio applicable to medical treatment, which depends on the type, severity, activity of a drug, It may be determined according to factors including sensitivity to the drug, administration time, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field.
이하, 본 발명을 구체적으로 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에 따른 여성청결제용 조성물은 제1유산균, 제2유산균 및 천년초(Opuntia humifusa) 추출물을 유효성분으로 포함한다. 이하, 본 발명에서 유효성분으로 사용하고 있는 제1유산균, 제2유산균 및 천년초(Opuntia humifusa) 추출물에 대해 설명한다.The composition for a feminine cleanser according to the present invention includes a first lactic acid bacteria, a second lactic acid bacteria, and a cheonnyeoncho ( Opuntia humifusa ) extract as active ingredients. Hereinafter, the first lactic acid bacteria, the second lactic acid bacteria, and the cheonnyeoncho ( Opuntia humifusa ) extract used as active ingredients in the present invention will be described.
제1유산균1st Lactobacillus
본 발명에서 여성청결제용 조성물의 유효성분으로 사용되는 제1유산균은 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 또는 이를 포함하는 배양물에서 선택된다. 본 발명에서 상기 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균은 여성청결제용 조성물의 칸디다 알비칸스(Candida albicans) 균에 대한 생장 억제 효과를 고려할 때 락토바실러스 플란타룸(Lactobacillus plantarum) MB01[기탁번호: KCTC 11877BP]인 것이 바람직하다. 상기 락토바실러스 플란타룸(Lactobacillus plantarum) MB01[기탁번호: KCTC 11877BP] 균주는 여성의 질에서 분리된 유산균으로서, 여성 질염의 예방 또는 개선 효과를 가지는 것으로 보고되었고(대한민국 등록특허공보 제10-1720145호 참조), 숙취해소용 조성물의 유효성분으로도 사용된바 있다(대한민국 공개특허공보 제10-2021-0000348호 참조).In the present invention, the first lactic acid bacteria used as an active ingredient of the composition for a feminine cleanser is selected from Lactobacillus plantarum lactic acid bacteria or a culture containing them. In the present invention, the Lactobacillus plantarum lactic acid bacteria are selected from the group consisting of Candida albicans in the composition for feminine cleanser, considering the growth inhibitory effect on the bacteria Lactobacillus plantarum MB01 [accession number: KCTC 11877BP] is preferred. The Lactobacillus plantarum MB01 [accession number: KCTC 11877BP] strain is a lactic acid bacterium isolated from the vagina of a woman, and has been reported to have an effect of preventing or improving female vaginitis (Korean Registered Patent Publication No. 10-1720145). Ho), it has also been used as an active ingredient in a composition for relieving hangover (see Korean Patent Publication No. 10-2021-0000348).
본 발명에서 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 배양물은 락토바실러스 플란타룸(Lactobacillus plantarum) 균주 배양액의 건조물로서, 더 구체적으로는 락토바실러스 플란타룸(Lactobacillus plantarum) 균주을 배지에 접종하고 배양하여 얻은 배양액을 스프레이 드라이, 동결건조 등의 방법으로 고형화시킨 것이며, 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 균체 및 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 배양에 의해 생성되는 대사산물을 포함한다. 본 발명에서 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 배양액을 제조하기 위해 사용되는 액체 배지는 MRS 액체 배지, GPY 액체 배지, GGPY 액체 배지, 포비돈이 첨가된 P-GPY 액체 배지, 포비돈이 첨가된 P-GGPY 액체 배지 등 공지의 다양한 액체 배지에서 선택될 수 있으며 특별히 제한되지 않는다. 다만, 락토바실러스 플란타룸(Lactobacillus plantarum) MB01[기탁번호: KCTC 11877BP] 균주의 빠른 성장을 고려하면 정제수 100L 당 함수결정포도당 2.5~3.5kg, 소이펩톤(soy peptone) 0.5~1.5kg, 효모 추출물 0.3~0.8kg, 구연산(citric acid) 0.15~0.35kg 및 제2인산칼륨(K2HPO4) 0.15~0.35kg을 포함시켜 액체 배지를 제조하는 것이 바람직하며, 정제수 100L 당 함수결정포도당 2.7~3.0kg, 소이펩톤(soy peptone) 0.85~1.2kg, 효모 추출물 0.4~0.55kg, 구연산(citric acid) 0.2~0.3kg 및 제2인산칼륨(K2HPO4) 0.2~0.3kg을 포함시켜 액체 배지를 제조하는 것이 더 바람직하다. 이후, 상기 액체 배지에 약 109~1012 CFU/mL의 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주를 상기 액체 배지의 전체 질량을 기준으로 0.005~2 중량%의 양으로 상기 액체배지에 접종하고 27~33℃에서 약 60~80 hr 동안 배양하면 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양액을 수득할 수 있다.In the present invention, Lactobacillus plantarum Lactobacillus culture is a dry matter of Lactobacillus plantarum strain culture, and more specifically, Lactobacillus plantarum strain is inoculated into a medium and cultured. The obtained culture medium is solidified by methods such as spray drying and freeze drying, and includes metabolites produced by culturing Lactobacillus plantarum lactic acid bacteria and Lactobacillus plantarum lactic acid bacteria. In the present invention, the liquid medium used to prepare the Lactobacillus plantarum lactic acid bacteria culture medium is MRS liquid medium, GPY liquid medium, GGPY liquid medium, P-GPY liquid medium with povidone added, and P with povidone added. -Can be selected from a variety of well-known liquid medium, such as GGPY liquid medium, and is not particularly limited. However, considering the rapid growth of the Lactobacillus plantarum MB01 [accession number: KCTC 11877BP] strain, 2.5 to 3.5 kg of hydrous crystalline glucose per 100 L of purified water, 0.5 to 1.5 kg of soy peptone, and yeast extract It is preferable to prepare a liquid medium by including 0.3 ~ 0.8kg, citric acid 0.15 ~ 0.35kg and dibasic potassium phosphate (K 2 HPO 4 ) 0.15 ~ 0.35kg, and 2.7 ~ 3.0 hydrous crystal glucose per 100L of purified water. kg, soy peptone 0.85-1.2 kg, yeast extract 0.4-0.55 kg, citric acid 0.2-0.3 kg and dibasic potassium phosphate (K 2 HPO 4 ) 0.2-0.3 kg to prepare a liquid medium. It is more preferable to manufacture Thereafter, about 10 9 ~ 10 12 CFU / mL of Lactobacillus plantarum MB01 strain is inoculated into the liquid medium in an amount of 0.005 to 2% by weight based on the total mass of the liquid medium. And when cultured at 27 ~ 33 ℃ for about 60 ~ 80 hr, Lactobacillus plantarum ( Lactobacillus plantarum ) MB01 strain culture can be obtained.
제2유산균2nd Lactobacillus
본 발명에서 여성청결제용 조성물의 유효성분으로 사용되는 제2유산균은 류코노스톡 김치아이(Leuconostoc kimchii) 유산균 또는 이를 포함하는 배양물에서 선택된다. 본 발명에서 상기 류코노스톡 김치아이(Leuconostoc kimchii) 유산균은 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균과의 병용에 의한 칸디다 알비칸스(Candida albicans) 균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균에 대한 성장 억제 효과를 고려할 때 류코노스톡 김치아이(Leuconostoc kimchii) MB1220[기탁번호: KCTC 12305BP]인 것이 바람직하다. 상기 류코노스톡 김치아이(Leuconostoc kimchii) MB1220[기탁번호: KCTC 12305BP] 균주는 김치에서 분리된 균주로서, 이의 사균체 및 배양 대사산물은 면역력 향상 또는 체지방 감소 효능을 갖는 것으로 보고된바 있다(대한민국 공개특허공보 제10-2021-0021791호 참조).In the present invention, the second lactic acid bacteria used as an active ingredient of the composition for a feminine cleanser is selected from Leuconostoc kimchii lactic acid bacteria or a culture containing the same. In the present invention, the Leuconostoc kimchii lactic acid bacteria are Lactobacillus plantarum Candida albicans bacteria and Gardnerella vaginalis bacteria by combination with lactic acid bacteria Considering the growth inhibitory effect on Leuconostoc Kimchi Ai ( Leuconostoc kimchii ) MB1220 [accession number: KCTC 12305BP] is preferred. The Leuconostoc kimchii MB1220 [accession number: KCTC 12305BP] strain is a strain isolated from kimchi, and its dead cells and cultured metabolites have been reported to have an effect of improving immunity or reducing body fat (Republic of Korea See Patent Publication No. 10-2021-0021791).
본 발명에서 류코노스톡 김치아이(Leuconostoc kimchii) 유산균 배양물은 류코노스톡 김치아이(Leuconostoc kimchii) 균주 배양액의 건조물로서, 더 구체적으로는 류코노스톡 김치아이(Leuconostoc kimchii) 균주을 배지에 접종하고 배양하여 얻은 배양액을 스프레이 드라이, 동결건조 등의 방법으로 고형화시킨 것이며, 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 균체 및 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 배양에 의해 생성되는 대사산물을 포함한다. 본 발명에서 락토바실러스 플란타룸(Lactobacillus plantarum) 유산균 배양액을 제조하기 위해 사용되는 액체 배지는 MRS 액체 배지, GPY 액체 배지, GGPY 액체 배지, 포비돈이 첨가된 P-GPY 액체 배지, 포비돈이 첨가된 P-GGPY 액체 배지 등 공지의 다양한 액체 배지에서 선택될 수 있으며 특별히 제한되지 않는다. 다만, 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주의 빠른 성장을 고려하면 정제수 100L 당 함수결정포도당 2.5~3.5kg, 소이펩톤(soy peptone) 0.75~1.6kg, 효모 추출물 0.2~1kg, 구연산(citric acid) 0.08~0.2kg 및 제2인산칼륨(K2HPO4)0.08~0.2kg을 포함시켜 액체 배지를 제조하는 것이 바람직하며, 정제수 100L 당 함수결정포도당 2.8~3.2kg, 소이펩톤(soy peptone) 1~1.3kg, 효모 추출물 0.4~0.8kg, 구연산(citric acid) 0.12~0.18kg 및 제2인산칼륨(K2HPO4) 0.12~0.18kg을 포함시켜 액체 배지를 제조하는 것이 더 바람직하다. 이후, 상기 액체 배지에 약 106~1010 CFU/mL의 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주를 상기 액체 배지의 전체 질량을 기준으로 0.005~2 중량%의 양으로 접종하고 27~33℃에서 24~72 hr 동안 배양하면 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양액을 수득할 수 있다.In the present invention, the Leuconostoc kimchi child ( Leuconostoc kimchii ) lactic acid bacteria culture is a dried product of the Leuconostoc kimchii strain culture, more specifically, the Leuconostoc kimchi child ( Leuconostoc kimchii ) strain is inoculated into the medium and cultured The obtained culture medium is solidified by methods such as spray drying and freeze drying, and includes metabolites produced by culturing Lactobacillus plantarum lactic acid bacteria and Lactobacillus plantarum lactic acid bacteria. In the present invention, the liquid medium used to prepare the Lactobacillus plantarum lactic acid bacteria culture medium is MRS liquid medium, GPY liquid medium, GGPY liquid medium, P-GPY liquid medium with povidone added, and P with povidone added. -Can be selected from a variety of well-known liquid medium, such as GGPY liquid medium, and is not particularly limited. However, considering the rapid growth of the Leuconostoc kimchii MB1220 strain, 2.5-3.5 kg of hydrous crystalline glucose per 100L of purified water, 0.75-1.6 kg of soy peptone, 0.2-1 kg of yeast extract, citric acid acid) 0.08 ~ 0.2kg and dibasic potassium phosphate (K 2 HPO 4 ) 0.08 ~ 0.2kg is preferably prepared to prepare a liquid medium, and 2.8 ~ 3.2kg of hydrous crystal glucose per 100L of purified water, soy peptone It is more preferable to prepare a liquid medium by including 1 to 1.3 kg, yeast extract 0.4 to 0.8 kg, citric acid 0.12 to 0.18 kg and dibasic potassium phosphate (K 2 HPO 4 ) 0.12 to 0.18 kg. Thereafter, about 10 6 ~ 10 10 CFU / mL Leuconostoc kimchi child ( Leuconostoc kimchii ) MB1220 strain is inoculated in an amount of 0.005 to 2% by weight based on the total mass of the liquid medium, and 27 to 33 When incubated for 24-72 hr at ℃ Leuconostoc Kimchi Ai ( Leuconostoc kimchii ) MB1220 strain culture medium can be obtained.
천년초(millennial plant ( Opuntia humifusaOpuntia humifusa ) 추출물) extract
본 발명에서 천년초(Opuntia humifusa) 추출물은 공지의 다양한 방법으로 제조될 수 있다. 상기 천년초(Opuntia humifusa)는 부채선인장아과(Opuntioideae) 부채선인장(Opuntia) 속에 속하는 다육 식물로서 "자단선선인장" 으로도 불리운다. 상기 천년초는 "백년초"로 불리는 보검선인장(Opuntia ficus-indica)과는 달리 영하 20℃의 혹한에서도 자체 수분을 절반 이하로 감소시켜 겨울 노지에서도 얼어 죽지 않는 강인한 생명력을 지닌 한국 토종의 선인장이다. 천년초의 가시를 제외한 줄기, 열매, 뿌리, 꽃은 각각의 영양성분 및 색소가 함유하고 있고, 천년초는 예로부터 소담제나 해열제로 쓰여왔다. 본 발명에서 천년초(Opuntia humifusa) 추출물을 얻기 위해 추출 원료로 천년초의 다양한 기관 또는 부위, 예를 들어 열매, 꽃, 줄기 또는 뿌리에서 선택되는 1종 이상의 부위를 사용할 수 있으며, 이 중 천년초 줄기를 사용하는 것이 바람직하다. 한편, 천년초로부터 추출물을 얻기 위해서는 추출 과정이 필요한데, 이때 추출 방법으로는 당업계에 공지된 통상의 추출 방법, 예를 들어 용매 추출법을 사용할 수 있다. 용매 추출법을 이용하여 천년초 추출물을 제조할 때 사용될 수 있는 추출 용매는 물, 탄소수 1 내지 4의 저급 알코올(예를 들면, 메탄올, 에탄올, 프로판올 및 부탄올) 또는 이들의 혼합물인 함수 저급 알코올, 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸 아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택될 수 있고, 이중 물, 알코올 또는 이들의 혼합물에서 선택되는 것이 바람직하다. 추출 용매로 물을 사용하는 경우 물은 열수인 것이 바람직하다. 또한, 추출 용매로 알코올을 사용하는 경우 알코올은 탄소수 1 내지 4의 저급 알코올인 것이 바람직하고, 저급 알코올은 메탄올 또는 에탄올에서 선택되는 것이 더 바람직하다. 또한, 추출 용매로 함수 알코올을 사용하는 경우 알코올 함량은 50~90%인 것이 바람직하다. 용매 추출법에 의해 수득한 천년초 추출액은 여과되어 여과된 추출액 형태로 회수되고, 감압증발기 등에 의해 농축되어 농축된 추출액 형태로 회수되고, 동결 건조 또는 스프레이 드라이와 같은 통상의 고상화 방법에 의해 추출물 분말 형태로 회수될 수 있다.In the present invention, cheonnyeoncho ( Opuntia humifusa ) The extract can be prepared by a variety of known methods. The cheonnyeoncho ( Opuntia humifusa ) is a succulent plant belonging to the Opuntioideae genus Opuntia and is also called "rosedan cactus". Unlike Opuntia ficus-indica , which is called "Baeknyeoncho", the cheonnyeoncho reduces its moisture to less than half even in the cold of minus 20 ° C. Stems, fruits, roots, and flowers, except for the thorns, contain nutrients and pigments, and Cheonnyeoncho has been used as a phlegm or antipyretic since ancient times. In the present invention, one or more parts selected from various organs or parts of Cheonnyeoncho, for example, fruits, flowers, stems, or roots, can be used as an extraction raw material to obtain an extract of Opuntia humifusa . It is desirable to do On the other hand, in order to obtain an extract from Cheonnyeoncho, an extraction process is required. At this time, as an extraction method, a conventional extraction method known in the art, for example, a solvent extraction method may be used. Extraction solvents that can be used when preparing Cheonnyeoncho extract using the solvent extraction method are water, lower alcohols having 1 to 4 carbon atoms (eg, methanol, ethanol, propanol and butanol), or mixtures thereof, such as hydrous lower alcohols, propylene glycol , 1,3-butylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane, and mixtures thereof, among which water, alcohol, or mixtures thereof It is preferable to be selected from When water is used as the extraction solvent, the water is preferably hot water. Further, when alcohol is used as the extraction solvent, the alcohol is preferably a lower alcohol having 1 to 4 carbon atoms, and the lower alcohol is more preferably selected from methanol or ethanol. In addition, when using hydrous alcohol as an extraction solvent, the alcohol content is preferably 50 to 90%. Cheonnyeoncho extract obtained by solvent extraction is filtered and recovered in the form of filtered extract, concentrated by vacuum evaporator, etc. can be recovered with
본 발명에 따른 여청청결제용 조성물에서 유효성분으로 사용되는 제1유산균:제2유산균:천년초(Opuntia humifusa) 추출물의 중량비는 칸디다 알비칸스(Candida albicans) 균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균의 생장 억제에 대한 시너지 효과나 경제성 등을 고려할 때 1:(0.5~2):(1~4)에서 선택되는 것이 바람직하고, 1:(0.75~1.5):(1.5~3)에서 선택되는 것이 더 바람직하다.The weight ratio of the first lactic acid bacteria: the second lactic acid bacteria: Cheonnyeoncho ( Opuntia humifusa ) extract used as an active ingredient in the cleaning composition according to the present invention is Candida albicans bacteria and Gardnerella vaginalis (Gardnerella Vaginalis) Considering the synergistic effect or economic feasibility of inhibiting bacterial growth, it is preferable to select from 1: (0.5 to 2): (1 to 4), and 1: (0.75 to 1.5): selected from (1.5 to 3) it is more preferable
본 발명에 따른 여성청결제용 조성물은 유효성분으로 사용되는 제1유산균, 제2유산균 및 천년초 추출물의 병용 처리에 의해 우수한 칸디다 알비칸스(Candida albicans) 균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균의 생장 억제 활성을 가지며, 칸디다 알비칸스(Candida albicans) 균 또는 가드네렐라 바지날리스(Gardnerella Vaginalis) 균에 의해 유발되는 질염을 효과적으로 예방, 개선 또는 치료할 수 있다.The composition for feminine cleansing according to the present invention is excellent Candida albicans bacteria and Gardnerella vaginalis bacteria by the combined treatment of the first lactic acid bacteria, the second lactic acid bacteria and the cheonnyeoncho extract used as active ingredients It has a growth inhibitory activity, and can effectively prevent, improve, or treat vaginitis caused by Candida albicans bacteria or Gardnerella Vaginalis bacteria.
본 발명에 따른 여성청결제용 조성물은 사용 목적 내지 양상에 따라 약학 조성물, 화장료 조성물, 퍼스널 케어 제품(personal care product) 등으로 구체화될 수 있다.The composition for feminine cleanser according to the present invention may be embodied as a pharmaceutical composition, cosmetic composition, personal care product, etc., depending on the purpose or aspect of use.
본 발명에 따른 약학 조성물은 유효성분 외에 약학적으로 허용가능한 담체, 부형제 또는 희석제와 같은 첨가제를 더 포함할 수 있다. 또한, 본 발명의 약학 조성물은 제1유산균, 제2유산균 및 천년초 추출물 추출물 외에 질 세정 또는 질염 개선 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다. 본 발명의 약학 조성물은 통상의 방법에 의해 비경구 투여를 위한 제형으로 제제화될 수 있고, 제제화할 경우 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함될 수 있다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 더 나아가 당 분야의 적정한 방법으로 또는 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다. 본 발명의 약학 조성물은 목적하는 방법에 따라 인간을 포함한 포유류에 비경구 투여될 수 있으며, 비경구 투여 방식으로는 피부 외용 등이 있다. 본 발명의 약학 조성물의 투여량은 약학적으로 유효한 양이라면 크게 제한되지 않으며, 환자 또는 사용자의 의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도에 따라 그 범위가 다양하다. 또한, 본 발명의 약학 조성물은 하루 1회 또는 수회로 나누어 투여될 수 있다. 본 발명에 따른 약학 조성물은 사용되는 양태를 고려할 때 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제와 같은 피부 외용 형태로 제조되는 것이 바람직하다.The pharmaceutical composition according to the present invention may further include additives such as pharmaceutically acceptable carriers, excipients or diluents in addition to active ingredients. In addition, the pharmaceutical composition of the present invention may further contain at least one known active ingredient having a vaginal cleansing or vaginitis improving effect in addition to the first lactic acid bacteria, the second lactic acid bacteria, and the Cheonnyeoncho extract extract. The pharmaceutical composition of the present invention may be formulated into a dosage form for parenteral administration by a conventional method, and when formulated, using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. can be formulated. Preparations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and ethyl oleate may be used as non-aqueous solvents and suspending solvents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used. Furthermore, it can be preferably formulated according to each disease or component by using an appropriate method in the art or by using a method disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA. The pharmaceutical composition of the present invention can be parenterally administered to mammals, including humans, according to a desired method, and parenteral administration includes external skin application. The dosage of the pharmaceutical composition of the present invention is not significantly limited as long as it is a pharmacologically effective amount, and depending on the patient's or user's weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of the disease Its range is diverse. In addition, the pharmaceutical composition of the present invention may be administered once or divided into several times a day. Considering the aspect of use, the pharmaceutical composition according to the present invention is preferably prepared in a form for external application to the skin such as a cream, gel, patch, spray, ointment, warning agent, lotion, liniment, pasta or cataplasma. .
본 발명에 따른 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 구체적으로, 본 발명의 화장료 조성물은 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다. 본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. 본 발명의 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다. 본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다. 본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸에테르와 같은 추진체를 포함할 수 있다. 본 발명의 화장료 조성물의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.The cosmetic composition according to the present invention may be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing It may be formulated as a cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. Specifically, the cosmetic composition of the present invention may be prepared in the form of flexible lotion, nutrient lotion, nutrient cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder. When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as a carrier component this can be used When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene fatty acid esters of glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan. When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester as a carrier component , microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth, and the like can be used. When the formulation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydro It may contain a propellant such as carbon, propane/butane or dimethyl ether. When the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, Fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters may be used.
본 발명에 따른 퍼스널 케어 제품(personal care product)은 스프레이형, 액상형, 젤형, 분말, 고형의 비누, 거품 타입의 세정제, 또는 물티슈 등으로 제형화될 수 있다.The personal care product according to the present invention may be formulated into a spray type, liquid type, gel type, powder, solid soap, foam type detergent, or wet tissue.
이하, 본 발명을 실시예를 통하여 보다 구체적으로 설명한다. 다만, 하기 실시예는 본 발명의 기술적 특징을 명확하게 예시하기 위한 것일 뿐, 본 발명의 보호범위를 한정하는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, the following examples are only for clearly illustrating the technical features of the present invention, but do not limit the protection scope of the present invention.
1. 유산균의 동정1. Identification of lactic acid bacteria
(1) 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주의 동정(1) Identification of Lactobacillus plantarum MB01 strain
락토바실러스 플란타룸(Lactobacillus plantarum) MB01([기탁번호: KCTC 11877BP])은 여성의 질에서 검사물을 수득하여 선별하였다. 구체적으로, 1999년 5월부터 서울, 대전, 인천에 위치한 산부인과 병원으로부터 200명이 넘는 여성의 검사물을 수득하였고, 강한 유산 발효능력을 가지고 있는 유산균을 선발하기 위하여 가급적 정상적인 미생물 균총을 가지고 있는 환자들의 검사물로부터 유산균 선별배지인 MRS배지(Difco 사, USA)를 활용하여 유산균을 선발하였다. 선발된 유용 유산균 생화학적 특성 중 사이즈는 마이크로미터 현미경을 이용하여 측정하였으며 그람 음성 및 그람 양성 판정은 Difco 사 제품의 그람 염색으로 판정하였다. 또한, 카탈라아제 테스트는 1% 과산화수소수 용액을 콜로니에 떨어뜨려 거품이 나는지 여부로 판정하였으며 pH 측정은 배양액에 pH 미터(Orion Star A211, Thermo, Singapore)를 사용하여 측정하였고 총산도 측정은 시료 10mL에 페놀프탈레인 용액 2~3방을 주입한 후 0.1N NaOH 용액에 서서히 첨가하면서 색이 변하는 순간까지 첨가한 NaOH 용액의 양에 0.059를 곱하여 환산하여 측정하였다. 실험결과는 하기 표 1에 나타내었고, 유산 발효 후의 최종 산도와 생존율 등을 감안하여 MB01을 최종 선발하였으며 상기 최종 선발된 MB01은 인하대학교 한홍의 교수 연구실 및 서울대학교 유전체 연구소에서 동정한 결과 Lactobacillus plantarum로 판명되었고 균주분류기준에 따라 락토바실러스 플란타룸(Lactobacillus plantarum) MB01로 명명하였다. 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주는 2011년 2월 23일에 공인기탁기관인 한국생명공학연구원 생물자원센터(주소: 대전시 유성구 과학로 111, 한국생명공학연구원 생물자원센터)에 특허기탁되어 KCTC 11877BP의 수탁번호를 부여받았다. Lactobacillus plantarum MB01 ([accession number: KCTC 11877BP]) was selected by obtaining a specimen from the vagina of a woman. Specifically, from May 1999, more than 200 women's test samples were obtained from obstetrics and gynecology hospitals located in Seoul, Daejeon, and Incheon, and in order to select lactic acid bacteria with strong lactic acid fermentation ability, patients with normal microflora were as much as possible. Lactic acid bacteria were selected from the specimens using MRS medium (Difco, USA), which is a lactic acid bacteria selection medium. Among the biochemical characteristics of the selected useful lactic acid bacteria, the size was measured using a micrometer microscope, and Gram-negative and Gram-positive judgments were determined by Difco's Gram staining. In addition, the catalase test was performed by dropping a 1% hydrogen peroxide solution on the colonies to determine whether or not bubbles were generated. The pH was measured using a pH meter (Orion Star A211, Thermo, Singapore) in the culture medium. After injecting 2-3 phenolphthalein solutions, it was measured by multiplying the amount of NaOH solution added by 0.059 until the color changed while slowly adding to the 0.1N NaOH solution. The experimental results are shown in Table 1 below, and MB01 was finally selected in consideration of the final acidity and survival rate after lactic acid fermentation. It was named Lactobacillus plantarum MB01 according to the strain classification criteria. Lactobacillus plantarum MB01 strain was patented on February 23, 2011 at the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center (address: 111 Gwahak-ro, Yuseong-gu, Daejeon, Korea Research Institute of Bioscience and Biotechnology Biological Resources Center), an official depository institution. It was given an accession number of KCTC 11877BP.
Colony
Colony
(㎛)Size of bacteria
(μm)
MB01
MB01
1.5
1.5
Positive
Positive
Negative
Negative
Positive
Positive
3.82
3.82
1.50
1.50
(2) 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주의 동정(2) Identification of Leuconostoc kimchii MB1220 strain
류코노스톡 김치아이(Leuconostoc kimchii) MB1220[기탁번호: KCTC 12305BP]은 김치를 파쇄하여 얻은 파쇄액을 수득하여 선별하였다. 구체적으로, 배추김치를 파쇄한 뒤, 파쇄액을 유산균 선별배지인 MRS배지(Difco 사, USA)에 넣고 현탁하였다. 이후, 상등액을 취해 MRS 한천 배지(Difco 사, USA)에 이식하고 약 37℃에서 약 48 hr 동안 혐기적으로 배양한 후, 콜로니를 형성한 60개 균주들을 분리하였다. 분리된 약 60개 균주 중에서 유산 발효 후의 최종 산도와 생존율 등을 감안하여 MB1220을 최종 선발하였고 상기 최종 선발된 MB1220은 생리학적 특성 및 16S rRNA 서열을 분석하여 균주의 종이 확정되었고 균주명이 부여되었다. 류코노스톡 김치아이(Leuconostoc kimchii) MB1220은 혐기성 구균(coccus)으로 그람 염색 시 양성을 나타내며 포자를 형성하지 않는 생리학적 특성을 가지고 있다. 또한, 류코노스톡 김치아이(Leuconostoc kimchii) MB1220의 화학분류학적 특성으로 16s ribosomal RNA gene sequence를 측정하였고 측정된 16S rRNA 염기서열을 Genebank(https://www.ncbi.nlm.nih.gov/)의 BLAST 검색으로 동정하였다. 그 결과, 동일한 16S rRNA 염기서열을 갖는 류코노스톡 김치아이(Leuconostoc kimchii) 균주는 검색되지 않았고, 류코노스톡 김치아이(Leuconostoc kimchii) IMSNU 11154 균주의 16S rRNA 부분 서열과 99%의 상동성을 보여 균주분류기준에 따라 류코노스톡 김치아이(Leuconostoc kimchii) MB1220으로 명명하였다. 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주는 2012년 11월 8일에 공인기탁기관인 한국생명공학연구원 생물자원센터(주소: 대전시 유성구 과학로 125, 한국생명공학연구원 생물자원센터)에 특허기탁되어 KCTC 12305BP의 수탁번호를 부여받았다. Leuconostoc kimchii MB1220 [accession number: KCTC 12305BP] was selected by obtaining a lysate obtained by crushing kimchi. Specifically, after crushing cabbage kimchi, the disrupted liquid was suspended in MRS medium (Difco, USA), which is a lactic acid bacteria selection medium. Thereafter, the supernatant was taken and transplanted to MRS agar medium (Difco, USA), cultured anaerobically at about 37° C. for about 48 hr, and then 60 strains forming colonies were isolated. Among the 60 isolated strains, MB1220 was finally selected in consideration of the final acidity and viability after lactic acid fermentation, and the finally selected MB1220 was analyzed for physiological characteristics and 16S rRNA sequence, and the strain species was determined and the strain name was assigned. Leuconostoc kimchii MB1220 is an anaerobic cocci (coccus) that shows positive in Gram staining and has physiological characteristics that do not form spores. In addition, the 16s ribosomal RNA gene sequence was measured as a chemical taxonomic characteristic of Leuconostoc kimchii MB1220, and the measured 16S rRNA sequence was transferred to Genebank (https://www.ncbi.nlm.nih.gov/). was identified by BLAST search of . As a result, Leuconostoc kimchii having the same 16S rRNA base sequence ( Leuconostoc kimchii ) strain was not searched, and Leuconostoc kimchii ( Leuconostoc kimchii ) 16S rRNA partial sequence of IMSNU 11154 strain and 99% showing homology It was named Leuconostoc kimchii MB1220 according to the strain classification criteria. Leuconostoc kimchii MB1220 strain was patented on November 8, 2012 at the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center (address: 125 Gwahak-ro, Yuseong-gu, Daejeon, Korea Research Institute of Bioscience and Biotechnology Biological Resources Center) It was given an accession number of KCTC 12305BP.
2. 유산균 배양물의 제조2. Preparation of lactic acid bacteria culture
(1) 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양물의 제조(1) Preparation of Lactobacillus plantarum MB01 strain culture
정제수 100L에 함수결정포도당 2.8 kg, 소이펩톤(soy peptone) 1 kg, 효모 추출물 0.5 kg, 구연산 0.25 kg 및 제2인산칼륨 0.25 kg을 포함시켜 액체 배지를 제조하였다. 이후, 상기 액체 배지에 약 1011 CFU/mL의 락토바실러스 플란타룸(Lactobacillus plantarum) MB01[기탁번호: KCTC 11877BP] 균주를 0.01 중량%의 양으로 접종하고 약 30℃에서 약 72 hr 동안 배양하여 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양액을 수득하였다. 이후, 상기 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양액을 동결건조하여 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양물을 수득하였다.A liquid medium was prepared by adding 2.8 kg of hydrous crystalline glucose, 1 kg of soy peptone, 0.5 kg of yeast extract, 0.25 kg of citric acid, and 0.25 kg of dibasic potassium phosphate to 100 L of purified water. Thereafter, about 10 11 CFU / mL of Lactobacillus plantarum MB01 [accession number: KCTC 11877BP] strain was inoculated in an amount of 0.01% by weight and cultured for about 72 hr at about 30 ° C. Lactobacillus plantarum ( Lactobacillus plantarum ) MB01 strain culture medium was obtained. Thereafter, the Lactobacillus plantarum MB01 strain culture was freeze-dried to obtain a Lactobacillus plantarum MB01 strain culture.
(2) 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양물의 제조(2) Preparation of Leuconostoc kimchii MB1220 strain culture
정제수 100L에 함수결정포도당 3.0 kg, 소이펩톤(soy peptone) 1.25 kg, 효모 추출물 0.6 kg, 구연산 0.15 kg 및 제2인산칼륨 0.15 kg을 포함시켜 액체 배지를 제조하였다. 이후, 상기 액체 배지에 약 108 CFU/mL 류코노스톡 김치아이(Leuconostoc kimchii) MB1220[기탁번호: KCTC 12305BP] 균주를 0.01 중량%의 양으로 접종하고 약 30℃에서 약 30 hr 동안 배양하여 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양액을 수득하였다. 이후, 상기 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양액을 동결건조하여 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양물을 수득하였다.A liquid medium was prepared by adding 3.0 kg of hydrous crystalline glucose, 1.25 kg of soy peptone, 0.6 kg of yeast extract, 0.15 kg of citric acid, and 0.15 kg of dibasic potassium phosphate to 100 L of purified water. Thereafter, about 10 8 CFU / mL Leuconostoc kimchi child ( Leuconostoc kimchii ) MB1220 [accession number: KCTC 12305BP] strain was inoculated in an amount of 0.01% by weight in the liquid medium and cultured at about 30 ° C. for about 30 hr, Conostock Kimchi Ai ( Leuconostoc kimchii ) MB1220 strain culture medium was obtained. Thereafter, the Leuconostoc kimchi kid ( Leuconostoc kimchii ) MB1220 strain culture was freeze-dried to obtain a Leuconostoc kimchi kid ( Leuconostoc kimchii ) MB1220 strain culture.
3. 천년초 추출물의 제조3. Preparation of Cheonnyeoncho Extract
천년초(Opuntia humifusa) 줄기를 건조한 후 분쇄하였다. 천년초 줄기 분쇄물에 70%(w/w) 농도의 에탄올 용액을 20배로 가한 후 40℃ 및 100 rpm 조건의 인큐베이터안에서 24 hr 동안 추출하고 여과하여 여과된 천년초 추출액을 수득하였다. 이후, 천년초 추출액을 감압농축한 후 동결건조하여 천년초 추출물을 수득하였다.Cheonnyeoncho ( Opuntia humifusa ) Stems were dried and then pulverized. A 20-fold 70% (w/w) concentration of ethanol solution was added to the pulverized Cheonnyeoncho stem, extracted for 24 hr in an incubator at 40 ° C and 100 rpm, and filtered to obtain a filtered Cheonnyeoncho extract. Thereafter, the extract of Cheonnyeoncho was concentrated under reduced pressure and then lyophilized to obtain an extract of Cheonnyeoncho.
4. 여성청결제용 조성물의 제조4. Preparation of composition for feminine cleanser
제조예 1.Preparation Example 1.
락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양물 25 중량부, 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양물 25 중량부 및 천년초 추출물 50 중량부를 균일하게 혼합하여 여성청결제용 조성물을 제조하였다.25 parts by weight of Lactobacillus plantarum MB01 strain culture, 25 parts by weight of Leuconostoc kimchii MB1220 strain culture, and 50 parts by weight of Cheonnyeoncho extract were uniformly mixed to prepare a composition for feminine cleansing. .
비교제조예 1.Comparative Preparation Example 1.
락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양물 50 중량부, 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양물 50 중량부를 균일하게 혼합하여 여성청결제용 조성물을 제조하였다.50 parts by weight of Lactobacillus plantarum MB01 strain culture and 50 parts by weight of Leuconostoc kimchii MB1220 strain culture were uniformly mixed to prepare a composition for a feminine cleanser.
비교제조예 2.Comparative Preparation Example 2.
락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양물 50 중량부 및 천년초 추출물 50 중량부를 균일하게 혼합하여 여성청결제용 조성물을 제조하였다.A composition for a feminine cleanser was prepared by uniformly mixing 50 parts by weight of the Lactobacillus plantarum MB01 strain culture and 50 parts by weight of the Cheonnyeoncho extract.
비교제조예 3.Comparative Preparation Example 3.
류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양물 50 중량부 및 천년초 추출물 50 중량부를 균일하게 혼합하여 여성청결제용 조성물을 제조하였다.A composition for a feminine cleanser was prepared by uniformly mixing 50 parts by weight of Leuconostoc kimchii MB1220 strain culture and 50 parts by weight of Cheonnyeoncho extract.
5. 여성청결제용 조성물의 칸디다 알비칸스(5. Candida albicans of composition for feminine wash ( Candida albicansCandida albicans )균 및 가드네렐라 바지날리스(Gardnerella Vaginalis) 균에 대한 생장 억제 효과 평가) Evaluation of growth inhibitory effect on bacteria and Gardnerella vaginalis (Gardnerella Vaginalis) bacteria
여성청결제용 조성물의 질염 원인균에 대한 생장 억제 효과를 평가하기 위하여 페이퍼디스크 확산법(Paper disk diffusion method)을 이용하였다. 또한, 대상 균주로 질염 발생 원인 진균류인 칸디다 알비칸스(Candida albicans) 및 질염 발생 원인 세균인 가드네렐라 바지날리스(Gardnerella vaginalis)를 사용하였다. 미리 배양된 칸디다 알비칸스 및 가드네렐라 바지날리스를 페이퍼디스크 확산법 측정용 평판배지에 100 ㎕씩 분주하여 도말하였다. 8 mm 지름의 페이퍼디스크(paper disk)에 시료를 5mg/disc의 농도로 점적하고 페이퍼디스크를 평판배지위에 올려놓았다. 상기 시료를 점적하기 위한 비히클로 10%(w/w) 에탄올 용액을 사용하였다. 양성 대조군으로 칸디다 알비칸스에 대해서는 항진균제인 이트라코나졸(Itraconazol), 가드네렐라 바지날리스에 대해서는 항생제인 앰피실린(Ampicillin)을 사용하였으며, 페이퍼디스크에 100㎍ /disk의 농도로 점적한 후 페이퍼디스크를 평판배지위에 올려놓았다. 또한, 음성 대조군으로 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양물, 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양물 및 천년초 추출물을 각각 사용하였다. The paper disk diffusion method was used to evaluate the growth inhibitory effect of the composition for feminine cleanser on the causative agent of vaginitis. In addition, Candida albicans , a fungus causing vaginitis, and Gardnerella vaginalis , a bacterium causing vaginitis, were used as target strains. Candida albicans and Gardnerella vaginalis, which were previously cultured, were plated by dispensing 100 µl each onto a plate medium for measuring the paper disc diffusion method. A sample was dropped at a concentration of 5 mg/disc on a paper disk having a diameter of 8 mm, and the paper disk was placed on a flat medium. A 10% (w/w) ethanol solution was used as a vehicle for dripping the sample. As a positive control, itraconazol, an antifungal agent for Candida albicans, and ampicillin, an antibiotic for Gardnerella vaginalis, were used. It was placed on a flat plate. In addition, as a negative control, Lactobacillus plantarum MB01 strain culture, Leuconostoc kimchii MB1220 strain culture and Cheonnyeoncho extract were used, respectively.
이후, 칸디다 알비칸스가 도말된 평판배지를 28℃에서 48 hr 동안 배양하고, 가드너렐라 바지날리스가 도말된 평판배지를 37℃에서 48 hr 동안 배양한 후, 페이퍼디스크 주위의 생육저지환(Clean Zone 또는 Inhibition Zone)의 직경을 측정하고, 그 결과를 하기 표 2에 나타내었다.Then, the plate medium smeared with Candida albicans was cultured at 28 ° C for 48 hr, and the plate medium smeared with Gardnerella vaginalis was cultured at 37 ° C for 48 hr. Zone or inhibition zone) was measured, and the results are shown in Table 2 below.
* 음성 대조군 1 : 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양물* Negative control 1: Lactobacillus plantarum ( Lactobacillus plantarum ) MB01 strain culture
* 음성 대조군 2 : 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양물* Negative control group 2: Leuconostoc kimchi child ( Leuconostoc kimchii ) MB1220 strain culture
* 음성 대조군 3 : 천년초 추출물* Negative control 3: Cheonnyeoncho extract
상기 표 2에서 보이는 바와 같이 락토바실러스 플란타룸(Lactobacillus plantarum) MB01 균주 배양물, 류코노스톡 김치아이(Leuconostoc kimchii) MB1220 균주 배양물 및 천년초 추출물을 혼합하여 제조한 여성청결제용 조성물은 구성성분들의 시너지 작용에 의해 질염 발생 원인 진균류인 칸디다 알비칸스(Candida albicans) 및 질염 발생 원인 세균인 가드네렐라 바지날리스(Gardnerella vaginalis)애 대해 매우 높은 생장 억제 효과를 나타내었다.As shown in Table 2, the composition for feminine cleanser prepared by mixing the Lactobacillus plantarum MB01 strain culture, the Leuconostoc kimchii MB1220 strain culture, and the Cheonnyeoncho extract contains the following components: It exhibited a very high growth inhibitory effect on Candida albicans , a fungus causing vaginitis, and Gardnerella vaginalis , a bacterium causing vaginitis, by synergistic action.
이상에서와 같이 본 발명을 실시예를 통해 설명하였지만 본 발명이 반드시 여기에만 한정되는 것은 아니며 본 발명의 범주와 사상을 벗어나지 않는 범위 내에서 다양한 변형실시가 가능함은 물론이다. 따라서, 본 발명의 보호범위는 본 발명에 첨부된 특허청구의 범위에 속하는 모든 실시 형태를 포함하는 것으로 해석되어야 한다.As described above, the present invention has been described through examples, but the present invention is not necessarily limited thereto, and various modifications are possible without departing from the scope and spirit of the present invention. Accordingly, the scope of protection of the present invention should be construed to include all embodiments falling within the scope of the claims appended hereto.
기탁기관명 : 한국생명공학연구원 생물자원센터(KCTC)Name of depositor: Korea Research Institute of Bioscience and Biotechnology Biological Resources Center (KCTC)
수탁번호 : KCTC11877BPAccession number: KCTC11877BP
수탁일자 : 20110223Entrusted date: 20110223
기탁기관명 : 한국생명공학연구원 생물자원센터(KCTC)Name of depositor: Korea Research Institute of Bioscience and Biotechnology Biological Resources Center (KCTC)
수탁번호 : KCTC12305BPAccession number: KCTC12305BP
수탁일자 : 20121108Entrusted date: 20121108
Claims (5)
Lactobacillus plantarum MB01 [accession number: KCTC 11877BP] lactic acid bacteria or a first lactic acid bacterium selected from a culture containing the same, Leuconostoc kimchii MB1220 [accession number: KCTC 12305BP] lactic acid bacteria or A composition for a feminine cleanser comprising a second lactic acid bacterium selected from a culture containing the same, and an extract of cheonnyeoncho ( Opuntia humifusa ) as an active ingredient.
According to claim 1, wherein the extract solvent of the cheonnyeoncho ( Opuntia humifusa ) Feminine cleanser composition, characterized in that selected from hot water, C1 to C4 lower alcohol or C1 to C4 hydrous lower alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220117612A KR102486025B1 (en) | 2022-09-19 | 2022-09-19 | Composition for feminine cleanser comprising live lactic acid bacteria and helpful for improving vaginitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220117612A KR102486025B1 (en) | 2022-09-19 | 2022-09-19 | Composition for feminine cleanser comprising live lactic acid bacteria and helpful for improving vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102486025B1 true KR102486025B1 (en) | 2023-01-09 |
Family
ID=84892863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220117612A KR102486025B1 (en) | 2022-09-19 | 2022-09-19 | Composition for feminine cleanser comprising live lactic acid bacteria and helpful for improving vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102486025B1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006512955A (en) * | 2003-01-09 | 2006-04-20 | 宏億生技股▲ふん▼有限公司 | Condoms coated with a composition containing lactic acid bacteria |
| KR101720145B1 (en) * | 2016-07-08 | 2017-04-07 | (주)정가진면역연구소 | Cosmetic composition for prevention and improvement of vaginosis |
| KR20190033397A (en) * | 2017-09-21 | 2019-03-29 | (주)정가진면역연구소 | A tea composition comprising Centella asiatica and lactic acid bacteria and The method for preparing thereof |
| KR20210119188A (en) * | 2020-03-24 | 2021-10-05 | 주식회사 밴드골드 | Feminine vulva cleanser and method for producing the same |
| KR20220097627A (en) * | 2020-12-30 | 2022-07-08 | 김선미 | a woman's genital cleaner |
-
2022
- 2022-09-19 KR KR1020220117612A patent/KR102486025B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006512955A (en) * | 2003-01-09 | 2006-04-20 | 宏億生技股▲ふん▼有限公司 | Condoms coated with a composition containing lactic acid bacteria |
| KR101720145B1 (en) * | 2016-07-08 | 2017-04-07 | (주)정가진면역연구소 | Cosmetic composition for prevention and improvement of vaginosis |
| KR20190033397A (en) * | 2017-09-21 | 2019-03-29 | (주)정가진면역연구소 | A tea composition comprising Centella asiatica and lactic acid bacteria and The method for preparing thereof |
| KR20210119188A (en) * | 2020-03-24 | 2021-10-05 | 주식회사 밴드골드 | Feminine vulva cleanser and method for producing the same |
| KR20220097627A (en) * | 2020-12-30 | 2022-07-08 | 김선미 | a woman's genital cleaner |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU783418B2 (en) | Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof | |
| US8222020B2 (en) | Biologically pure strain of Lactobacillus fermentum, strain Ess-1 | |
| US7618658B2 (en) | Anti-microbial agent and anti-microbial composition | |
| KR101287126B1 (en) | Pharmaceutical compositon prevention and treatment of vaginitis and urinary tract infection comprising fermented solution of plant-originated Lactic acid bacteria | |
| TWI784210B (en) | Composition and vaginal cleaning composition for inhibiting of vaginal pathogens and uses thereof | |
| KR101860513B1 (en) | Pharmaceutical composition for preventing or treating candidal colpitis comprising Lactobacillus salivarius MG242 isolated from human vagina | |
| KR102486025B1 (en) | Composition for feminine cleanser comprising live lactic acid bacteria and helpful for improving vaginitis | |
| CN101543514A (en) | Compound lactobacillus vagina cleaning hygiene body lotion for preventing or treating vaginitis and technology thereof | |
| KR101198572B1 (en) | Composition for treatment or improvement of microbial infection | |
| KR20230128540A (en) | Strains, compositions and methods of use | |
| RU2413761C1 (en) | Lactobacillus fermentum Ess-1, DSM17851, AND ITS APPLICATION FOR TREATMENT AND/OR PREVENTION OF CANDIDOSIS AND URINARY TRACT INFECTIONS | |
| KR102245617B1 (en) | Feminine cleanser comprising extract of rose and extract of Sanguisorba officinalis root | |
| KR20060128125A (en) | Agent for the treatment of vaginitis containing mandelic acid as an active ingradient | |
| KR102248786B1 (en) | Feminine cleanser comprising extract of mugwort and extract of Sanguisorba officinalis root | |
| US20240050493A1 (en) | Strains, compositions and methods of use | |
| KR102519415B1 (en) | Composition for preventing or treating vaginitis | |
| KR20210054206A (en) | Feminine cleanser comprising extract of mugwort and extract of rose | |
| CN116801893A (en) | Strains, compositions and methods of use | |
| CN117062614A (en) | Strains, compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |